Sectors
AVTX
Avalo Therapeutics, Inc.
19.18
1 x 13.79
1 x 19.23
bid
ask
-
0.41
2.09%
02:11 PM
timesize
| Ytd | 5.62% | |
| 1y | 106.46% |
19.05
day range
19.58
8.65
52 week range
24.27
| Open | 19.40 | Prev Close | 19.59 | Low | 19.05 | High | 19.58 | Mkt Cap | 1.03B |
| Vol | 326.48K | Avg Vol | 1.29M | EPS | -4.41 | P/E | N/A | Forward P/E | -7.44 |
| Beta | 0.80 | Short Ratio | 16.53 | Inst. Own | 133.34% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 18.90 | 200-d Avg | 16.83 | 1yr Est | 44.15 |
| Income Statement | |||
| Operating Expenses | 31.52M | ||
| Research and Development Expense | 23.42M | ||
| Selling, General and Administrative Expense | 8.10M | ||
| Operating Income | -31.52M | ||
| Income Tax Expense | 18.00K | ||
| Net Income | -36.36M | ||
| Net Income Common Stock | -36.36M | ||
| Net Income Common Stock (USD) | -36.36M | ||
| Consolidated Income | -36.36M | ||
| Earnings per Basic Share | -0.83 | ||
| Earnings per Basic Share (USD) | -0.83 | ||
| Earnings per Diluted Share | -0.83 | ||
| Earning Before Interest & Taxes (EBIT) | -36.34M | ||
| Earning Before Interest & Taxes (USD) | -36.34M | ||
| Weighted Average Shares | 43.60M | ||
| Weighted Average Shares Diluted | 43.60M | ||
| Balance Sheet | |||
| Cash and Equivalents | 85.43M | ||
| Cash and Equivalents (USD) | 85.43M | ||
| Investments | 386.96M | ||
| Investments Current | 314.89M | ||
| Investments Non-Current | 72.06M | ||
| Current Assets | 407.93M | ||
| Property, Plant & Equipment Net | 288.00K | ||
| Total Assets | 490.78M | ||
| Current Liabilities | 21.13M | ||
| Total Liabilities | 42.12M | ||
| Accumulated Retained Earnings (Deficit) | -504.51M | ||
| Accumulated Other Comprehensive Income | -583.00K | ||
| Shareholders Equity | 448.66M | ||
| Shareholders Equity (USD) | 448.66M | ||
| Assets Non-Current | 82.85M | ||
| Goodwill and Intangible Assets | 10.50M | ||
| Liabilities Non-Current | 20.99M | ||
| Trade and Non-Trade Payables | 3.35M | ||
| Tax Liabilities | 463.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 17.00K | ||
| Net Cash Flow from Financing | 410.21M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 60.30M | ||
| Issuance (Purchase) of Equity Shares | 410.21M | ||
| Net Cash Flow from Investing | -329.92M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -329.92M | ||
| Net Cash Flow from Operations | -19.99M | ||
| Share Based Compensation | 5.31M | ||